Healthcare company Avrio Health LP said on Thursday that the Betadine Antiseptic Sore Throat Gargle (active ingredient, povidone-iodine or PVP-I) killed 99.9% of the COVID-19 virus within 15 seconds in an in vitro (laboratory) study.
The company added that the Betadine Gargle containing 0.5% PVP-I demonstrated virucidal activity against SARS-CoV-2 and four surrogate coronaviruses in separate in vitro studies conducted by Utah State University, Institute for Antiviral Research, BluTest Laboratories, Tropical Infectious Diseases Research and Education Center at the University of Malaya, Malaysia as well as the Duke-NUS Medical School in Singapore.
According to the company, Betadine Antiseptic Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be swallowed, is an oral antiseptic with use for the temporary relief of occasional sore throat. Betadine Antiseptic Sore Throat Gargle will be available in retail stores in late August 2020. All products should be used only as directed on the label.
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Astellas to present VEOZAH (fezolinetant) data at Menopause Society 2025 Annual Meeting
Imaging Biometrics acquires Kirkstall to expand presence in advanced cell culture technologies
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference